CCL2 and breast cancer: Conclusively, data from in vitro and in vivo experiments confirm that miR-375 from breast cancer cells increases monocytes/MΦ migration by targeting PXN and TNS3. Furthermore, depletion of miR-375 in breast cancer cells reduces CCL2 secretion, thereby attenuating their chemoattractive properties.